Patent · US Active

Anti-OX40L antibodies

US9102733B2 · kind B2 · utility

20Cited by

21References

17Claims

0Family size

Assignee

Roche Palo Alto LLC · US

Inventors

Joseph Endl · Bad Birnbach, DE
Elsie M. Eugui · Belmont, US
Maria Elena Fuentes · Sunnyvale, US
Yvo Graus · Ede, NL
Aran Frank Labrijn · Amsterdam, NL
Martin Lanzendoerfer · Tutzing, DE
Paul Parren · Utrecht, NL
Frank Rebers · Utrecht, NL
Ralf Schumacher · Penzberg, DE
Stefan Seeber · Penzberg, DE
Jan Van De Winkel · Utrecht, NL
Martine Van Vugt · Houten, NL

Key dates

Filing date	Dec 1, 2010
Grant date	Aug 11, 2015
Priority date	—
Expiry date	Jan 25, 2034

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/56
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This invention relates to anti-OX40L antibodies and, in particular, to anti-OX40L antibodies and variants thereof that contain a Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from inflammatory diseases.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.